List of Supplementary Protection Certificates

Biologic Drug Supplementary Protection Certificates

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.

Country	Patent Number	Supplementary Protection Certificate	SPC Country	SPC Description	SPC Expiration
European Patent Office	2161336	C 2015 054	Romania	PRODUCT NAME: NIVOLUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1014; DATE OF NATIONAL AUTHORISATION: 20150619; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1014; DATE OF FIRST AUTHORISATION IN EEA: 20150619
European Patent Office	2081595	132019000000125	Italy	PRODUCT NAME: DARATUMUMAB, LENALIDOMIDE E DESAMETASONE(DARZALEX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1101/001-002, 20170503
European Patent Office	3095795	C03095795/01	Switzerland	PRODUCT NAME: RAVULIZUMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67278 16.02.2023
European Patent Office	1625209	C20160007	Estonia	PRODUCT NAME: EFMOROKTOKOG ALFA; NATIONAL AUTHORISATION NUMBER: EMA/305524/2019; DATE OF AUTHORISATION: 20190604
European Patent Office	2170959	2015C/080	Belgium	PRODUCT NAME: GEHUMANISEERD MONOCLONAAL ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTILICHAAM MET LICHTE KETEN CDRS SEQ ID NOS:15, 16 EN 17 EN ZWARE KETEN CDRS SEQ ID NOS:18, 19 EN 20, IN HET BIJZONDER PEMBROLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/15/1024/001 20150721
European Patent Office	1809237	C01809237/01	Switzerland	PRODUCT NAME: CICLOSPORIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66093 08.09.2016